- Home
- JAMF vs TSHA Comparison
JAMF vs TSHA Comparison
Compare JAMF & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAMF
- TSHA
- Stock Information
- Founded
- JAMF 2002
- TSHA 2019
- Country
- JAMF United States
- TSHA United States
- Employees
- JAMF N/A
- TSHA N/A
- Industry
- JAMF Computer Software: Prepackaged Software
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- JAMF Technology
- TSHA Health Care
- Exchange
- JAMF Nasdaq
- TSHA Nasdaq
- Market Cap
- JAMF 1.4B
- TSHA 1.4B
- IPO Year
- JAMF 2020
- TSHA 2020
- Fundamental
- Price
- JAMF $10.67
- TSHA $4.82
- Analyst Decision
- JAMF Buy
- TSHA Strong Buy
- Analyst Count
- JAMF 11
- TSHA 9
- Target Price
- JAMF $16.27
- TSHA $10.00
- AVG Volume (30 Days)
- JAMF 1.4M
- TSHA 11.7M
- Earning Date
- JAMF 11-10-2025
- TSHA 11-12-2025
- Dividend Yield
- JAMF N/A
- TSHA N/A
- EPS Growth
- JAMF N/A
- TSHA N/A
- EPS
- JAMF N/A
- TSHA N/A
- Revenue
- JAMF $666,382,000.00
- TSHA $8,098,000.00
- Revenue This Year
- JAMF $14.24
- TSHA N/A
- Revenue Next Year
- JAMF $9.60
- TSHA N/A
- P/E Ratio
- JAMF N/A
- TSHA N/A
- Revenue Growth
- JAMF 11.36
- TSHA N/A
- 52 Week Low
- JAMF $7.09
- TSHA $1.05
- 52 Week High
- JAMF $18.00
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- JAMF 56.65
- TSHA 57.99
- Support Level
- JAMF $10.40
- TSHA $4.77
- Resistance Level
- JAMF $10.73
- TSHA $5.33
- Average True Range (ATR)
- JAMF 0.32
- TSHA 0.37
- MACD
- JAMF 0.01
- TSHA -0.07
- Stochastic Oscillator
- JAMF 92.49
- TSHA 35.71
About JAMF Jamf Holding Corp.
Jamf Holding Corp is the standard in Apple Enterprise Management, and its cloud software platform is the vertically focused Apple infrastructure and security platform. The company helps organizations, including businesses, hospitals, schools, and government agencies, connect, manage, and protect Apple products, apps, and corporate resources in the cloud without ever having to touch the devices. It sells its Software-as-a-Service, or SaaS, solutions via a subscription model, through a direct sales force, online, and indirectly via its channel partners, including Apple. The company operates in The Americas; Europe, the Middle East, India, and Africa; and Asia Pacific.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.